Hangzhou Tigermed Consulting Co., Ltd (SHE:300347)

China flag China · Delayed Price · Currency is CNY
58.39
+1.53 (2.69%)
Apr 28, 2026, 3:09 PM CST
29.61%
Market Cap 47.29B
Revenue (ttm) 6.83B
Net Income (ttm) 887.89M
Shares Out 855.14M
EPS (ttm) 1.04
PE Ratio 56.28
Forward PE 47.04
Dividend 0.13 (0.22%)
Ex-Dividend Date Jun 17, 2025
Volume 18,303,733
Average Volume 12,659,088
Open 56.86
Previous Close 56.86
Day's Range 55.80 - 59.50
52-Week Range 41.61 - 71.90
Beta 0.68
RSI 56.24
Earnings Date Mar 30, 2026

About SHE:300347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, includ... [Read more]

Sector Healthcare
Founded 2004
Employees 11,130
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300347
Full Company Profile

Financial Performance

In 2025, SHE:300347's revenue was 6.83 billion, an increase of 3.48% compared to the previous year's 6.60 billion. Earnings were 887.89 million, an increase of 119.15%.

Financial Statements

News

There is no news available yet.